Inozyme Pharma Reports Third Quarter 2024 Financial Results and Provides Business HighlightsGlobeNewsWire • 11/05/24
Inozyme Pharma Announces Positive Interim Data from Phase 1 SEAPORT 1 Trial of INZ-701GlobeNewsWire • 10/24/24
Inozyme Pharma Announces Presentation of Interim Data from Phase 1 SEAPORT 1 Trial at the Upcoming American Society of Nephrology (ASN) Kidney Week 2024GlobeNewsWire • 10/17/24
Inozyme Pharma Announces Appointment of Biopharmaceutical Commercial Leader Erik Harris to its Board of DirectorsGlobeNewsWire • 10/07/24
Why Analyst Says Rare Disease-Focused Inozyme Pharma Stock 'Could Be Worth A Look'Benzinga • 09/12/24
Inozyme Pharma Publishes Preclinical Data Supporting INZ-701 as a Potential Therapy for a Broad Range of Serious Rare Diseases Impacting Bone Health and Blood Vessel FunctionGlobeNewsWire • 07/25/24
Inozyme Pharma Announces FDA Fast Track Designation for INZ-701 in ABCC6 DeficiencyGlobeNewsWire • 07/02/24
Inozyme Pharma Announces Presentation and Sponsored Symposium at the 11th International Conference on Children's Bone Health (ICCBH)GlobeNewsWire • 06/21/24
Inozyme Pharma to Present Recently Announced Data from Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE) at Upcoming Medical ConferencesGlobeNewsWire • 05/23/24
Inozyme Pharma to Participate at the Bank of America Securities 2024 Health Care ConferenceGlobeNewsWire • 05/08/24
Inozyme Pharma Reports First Quarter 2024 Financial Results and Provides Business HighlightsGlobeNewsWire • 05/07/24
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 05/03/24
Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 DeficiencyGlobeNewsWire • 04/08/24
Inozyme Pharma to Participate at the 23rd Annual Needham Virtual Healthcare ConferenceGlobeNewsWire • 04/02/24
Inozyme Pharma to Report Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency and ENPP1 Deficiency on April 8, 2024GlobeNewsWire • 03/26/24
Inozyme Pharma Reports Full Year 2023 Financial Results and Provides Business HighlightsGlobeNewsWire • 03/12/24
Inozyme Pharma to Participate in the TD Cowen 44th Annual Health Care ConferenceGlobeNewsWire • 02/26/24
Inozyme Pharma Reports Third Quarter 2023 Financial Results and Provides Business HighlightsGlobeNewsWire • 11/07/23
Inozyme Pharma, Inc. (INZY) Moves to Buy: Rationale Behind the UpgradeZacks Investment Research • 10/10/23